8 Most Promising Healthcare Stocks According to Hedge Funds

4. Johnson & Johnson (NYSE:JNJ)

Number of Hedge Fund Holders: 81 

Johnson & Johnson (NYSE:JNJ) is a global healthcare giant that operates in three main segments: pharmaceuticals, medical devices, and consumer health products. The company develops and manufactures a wide range of products, from everyday items like Band-Aids and Tylenol to advanced medical devices and innovative prescription drugs.

The regulatory approvals for RYBREVANT and TREMFYA have been acquired by Johnson & Johnson (NYSE:JNJ). The company strengthened its position in cardiovascular intervention and medical technology by acquiring Shockwave Medical in April. It is anticipated that all segments will rise at a compound annual growth rate of 5–7% between 2025 and 2030. Furthermore, there are about ten assets in the Innovative Medicine sector that might generate over $5 billion in expected operational sales each.

Johnson & Johnson (NYSE:JNJ) is a strong dividend payer, having raised its payouts for over 60 consecutive years. The company offers a quarterly dividend of $1.24 per share for a dividend yield of over 3%.

As of Q3 2024, 81 hedge funds tracked by Insider Monkey held stakes in Johnson & Johnson (NYSE:JNJ) with Fisher Asset Management being the largest stakeholder with stakes worth over $1.2 billion.